Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CCL22 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | O00626 |
|---|---|
| Clone Names | 100507234 |
| Gene ID | 6367 |
|---|---|
| Other Names | C-C motif chemokine 22, CC chemokine STCP-1, MDC(1-69), Macrophage-derived chemokine, Small-inducible cytokine A22, Stimulated T-cell chemotactic protein 1, MDC(3-69), MDC(5-69), MDC(7-69), CCL22, MDC, SCYA22 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | CCL22 |
|---|---|
| Synonyms | MDC, SCYA22 |
| Function | May play a role in the trafficking of activated/effector T- lymphocytes to inflammatory sites and other aspects of activated T- lymphocyte physiology. Chemotactic for monocytes, dendritic cells and natural killer cells. Mild chemoattractant for primary activated T- lymphocytes and a potent chemoattractant for chronically activated T- lymphocytes but has no chemoattractant activity for neutrophils, eosinophils, and resting T-lymphocytes. Binds to CCR4. Processed forms MDC(3-69), MDC(5-69) and MDC(7-69) seem not be active. |
| Cellular Location | Secreted. |
| Tissue Location | Highly expressed in macrophage and in monocyte- derived dendritic cells, and thymus. Also found in lymph node, appendix, activated monocytes, resting and activated macrophages. Lower expression in lung and spleen. Very weak expression in small intestine In lymph node expressed in a mature subset of Langerhans' cells (CD1a+ and CD83+). Expressed in Langerhans' cell histiocytosis but not in dermatopathic lymphadenopathy. Expressed in atopic dermatitis, allergic contact dermatitis skin, and psoriasis, in both the epidermis and dermis. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CCL22 is one of several Cys-Cys (CC) cytokine genesclustered on the q arm of chromosome 16. Cytokines are a family ofsecreted proteins involved in immunoregulatory and inflammatoryprocesses. The CC cytokines are proteins characterized by twoadjacent cysteines. The cytokine encoded by this gene displayschemotactic activity for monocytes, dendritic cells, natural killercells and for chronically activated T lymphocytes. It also displaysa mild activity for primary activated T lymphocytes and has nochemoattractant activity for neutrophils, eosinophils and resting Tlymphocytes. The product of this gene binds to chemokine receptorCCR4. This chemokine may play a role in the trafficking ofactivated T lymphocytes to inflammatory sites and other aspects ofactivated T lymphocyte physiology.
References
Toulza, F., et al. J. Immunol. 185(1):183-189(2010)Maruyama, T., et al. Dis. Esophagus 23(5):422-429(2010)Schuurhof, A., et al. Pediatr. Pulmonol. 45(6):608-613(2010)Wu, C., et al. Respirology 15(3):522-529(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
